I. Bieche et al., ERBB2 status and benefit from adjuvant tamoxifen in ER alpha-positive postmenopausal breast carcinoma, CANCER LETT, 174(2), 2001, pp. 173-178
We examined the relation between ERBB2 gene expression (as determined by a
real-time quantitative RT-PCR assay) and the response to adjuvant tamoxifen
therapy in a well-defined cohort of 125 ER alpha -positive postmenopausal
patients with breast cancer. Although ERBB2 overexpression was associated w
ith shorter relapse-free survival in univariate analysis (P = 0.00029), ERB
B2 did not persist as an independent prognostic factor in multivariate anal
ysis. Nevertheless, when we analyzed the ERBB2 mRNA level as a continuous v
ariable, the higher the ERBB2RNA level, the poorer the outcome (P = 0.00036
). The results point to the need for a quantitative ERBB2 expression assay
for use in future studies of ERBB2-based clinical management of breast canc
er. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.